Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average – Should You Sell?

Vistagen Therapeutics, Inc. (NASDAQ:VTGN)’s share price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.82 and traded as high as $2.84. Vistagen Therapeutics shares last traded at $2.77, with a volume of 206,572 shares trading hands.

Vistagen Therapeutics Price Performance

The stock has a market capitalization of $79.95 million, a P/E ratio of -1.87 and a beta of 0.62. The firm has a 50-day simple moving average of $2.82 and a 200 day simple moving average of $2.88.

Vistagen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings data on Thursday, February 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02. Vistagen Therapeutics had a negative return on equity of 48.12% and a negative net margin of 6,777.08%. The company had revenue of $230 billion during the quarter, compared to the consensus estimate of $0.18 million. Sell-side analysts anticipate that Vistagen Therapeutics, Inc. will post -1.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vistagen Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. R Squared Ltd bought a new stake in shares of Vistagen Therapeutics during the fourth quarter valued at approximately $25,000. Two Sigma Advisers LP bought a new stake in shares of Vistagen Therapeutics during the fourth quarter valued at approximately $35,000. Man Group plc bought a new stake in shares of Vistagen Therapeutics during the fourth quarter valued at approximately $54,000. Jane Street Group LLC bought a new stake in shares of Vistagen Therapeutics during the third quarter valued at approximately $59,000. Finally, Virtu Financial LLC increased its holdings in shares of Vistagen Therapeutics by 30.5% during the third quarter. Virtu Financial LLC now owns 20,210 shares of the company’s stock valued at $61,000 after acquiring an additional 4,722 shares in the last quarter. 78.39% of the stock is currently owned by institutional investors.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.